ADC Therapeutics stock faces FDA hurdles as runway extends to 2029
Published on 11/11/2026 at 03:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey developments for investors
- ADC Therapeutics reported higher third-quarter product revenue and a lower net loss than a year earlier.
- A financing and debt restructuring strengthened the balance sheet and extended the expected cash runway.
- ZYNLONTA remains central to the company's clinical and commercial strategy, with new data due at ASH.
ADC Therapeutics reported third-quarter results on Monday, November 9, 2026, highlighting stronger product sales, a narrower loss and a reinforced financing position. The PR Newswire release said net product revenue reached 21.0 million US dollars in the quarter, up from 15.8 million US dollars a year earlier.
ADC Therapeutics also reported total revenue of 21.7 million US dollars and a net loss of 25.3 million US dollars, or 0.16 US dollars per share. On an adjusted basis, the net loss was 8.8 million US dollars, or 0.06 US dollars per share, compared with an adjusted loss of 25.5 million US dollars, or 0.19 US dollars per share, in the prior-year quarter.
Financing supports clinical priorities
An October restructuring included an 86.6 million US dollar private investment in public equity. The company said the transaction reduced senior secured loan principal by 68.5 million US dollars to 50 million US dollars, removed scheduled principal amortization and extended the expected cash runway into 2029.
Cash and cash equivalents stood at 189.2 million US dollars at September 30, down from 261.3 million US dollars at the end of 2025. The financing gives management more room to fund ZYNLONTA development while the company continues to absorb the costs of commercial operations and clinical programs.
ZYNLONTA milestones move closer
ADC Therapeutics plans five oral presentations at the American Society of Hematology annual meeting in December. The program includes updated LOTIS-7 results for ZYNLONTA combined with glofitamab, full LOTIS-5 results and investigator-initiated studies in marginal zone lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinemia.
The company also said its Japanese partner, Tanabe Pharma, submitted a marketing authorization application for ZYNLONTA in relapsed or refractory diffuse large B-cell lymphoma after at least two lines of systemic therapy. These developments leave regulatory execution and the durability of commercial growth as key factors for investors.
ADCT stock traded at 1.51 US dollars on the New York Stock Exchange at 4:00 p.m. Eastern Time on Tuesday, November 10, 2026. The latest quote provides a current market reference, while a dated Xetra comparison is not used for this US-listed security.
ADC Therapeutics business profile
ADC Therapeutics is a commercial-stage biotechnology company headquartered in Epalinges, Switzerland, with operations in New Jersey. It develops antibody-drug conjugates for hematological malignancies and solid tumors, led by the CD19-directed product ZYNLONTA. The company combines clinical development, manufacturing and commercialization capabilities and maintains partnerships for selected programs and markets.
ADC Therapeutics at a glance
- Company: ADC Therapeutics S.A.
- ISIN: CH0499880968
- Ticker: ADCT
- Exchange: New York Stock Exchange
- Latest quote: 1.51 US dollars at 4:00 p.m. Eastern Time on November 10, 2026
- Sector: Healthcare
- Industry: Biotechnology
The broader US equity market remains the relevant market backdrop for the NYSE-listed security. See current S&P 500 market coverage.
